Overview

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine will be acceptable and tolerable as an approach to managing physical dependence on opioids in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Pennsylvania
Collaborators:
Durham VA Health Care System
Durham VA Healthcare System
Hennepin Health Care
Massachusetts General Hospital
New York University
Rogosin Institute
University of Illinois at Chicago
University of New Mexico
University of Pennsylvania
University of Pittsburgh
University of Washington
VA Portland Healthcare System
Vanderbilt University Medical Center
West Haven VA Medical Center
West Virginia University
Yale University
Treatments:
Buprenorphine